市场调查报告书

失眠症治疗的全球市场:成长,趋势,及预测

Insomnia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 704962
出版日期 内容资讯 英文 114 Pages
商品交期: 2-3个工作天内
价格
Back to Top
失眠症治疗的全球市场:成长,趋势,及预测 Insomnia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 114 Pages
简介

本报告提供全球失眠症治疗市场的相关调查,市场机会和课题,成长及阻碍因素,各治疗类型、流通管道、地区的市场分析,竞争情形,主要企业的简介等资讯。

目录

第1章 简介

  • 调查成果
  • 调查的假设
  • 调查范围

第2章 调查方法

第3章 摘要整理

第4章 市场动态

  • 市场概况
  • 成长要素
  • 阻碍因素
  • 波特的五力分析
    • 新加入厂商的威胁
    • 买主/消费者谈判力
    • 供应商谈判力
    • 替代产品的威胁
    • 产业内的竞争

第5章 市场区隔

  • 各治疗类型
    • 苯重氮基鹽
    • Non苯重氮基鹽
    • 抗忧鬱症药
    • Orexin拮抗剂
    • 褪黑激素拮抗剂
    • 其他
  • 各流通管道
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲地区
    • 南美

第6章 竞争情形

  • 企业简介
    • Merck & Co.
    • Mylan N.V.
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • 大日本住友制药株式会社
    • 武田药品工业株式会社
    • Teva Pharmaceutical Industries Ltd.
    • Vanda Pharmaceuticals Inc.

第7章 市场机会及未来趋势

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 62832

In a study published in PMC in 2015 by "Hindawi Journal" (by Timothy Fitzgerald and Jeffrey Vietri), it was revealed that approximately 25% of US adults have conveyed discontent regarding their sleep, of which 10 to 15% claim to experienced insomnia symptoms and 6-10% suffer from insomnia. The study also shows that approximately 70% of patients suffering from partial stages of insomnia also end up reporting insomnia disorder within one year, and 50% of that population continues to suffer from the symptoms for the next three years. The study suggests that insomnia has become one of the most prevalent disorders being reported in the primary care setup. Also, a high comorbidity rate has been observed between insomnia and medical or some psychiatric disorders. These statistics are a direct consequence of the increasing stress due to the current lifestyle of the urban population.

The other factors such as side effects due to certain OTC and prescription medication, arthritis, high usage of media devices before sleep, are driving the number of people suffering from insomnia, thus boosting the market growth prospects. Moreover, the growth of psychological conditions and constantly increasing noise levels in the urban areas will also propel the insomnia treatment market, during the forecast period.

Key Market Trends

Orexin Antagonist segment is expected to grow in the forecast period

The global insomnia treatment market is segmented based on treatment type, which includes benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonist, melatonin antagonist, and other treatment types. The distribution channel includes hospital pharmacies, retail pharmacies and drug stores, and online pharmacies.

The insomnia drugs comprise of a wide range of patented drugs, as well as generics. The patented drugs hold a larger share in developed regions, owing to the better reimbursement policies. The orexin antagonist segment is expected to grow rapidly during the forecast period due to its greater efficacy than other drugs.

North America is expected to dominate the Insomnia Treatment market

North America leads the insomnia treatment market. The growing need for sleep disorder treatment in the US and Canada coupled with the growing prevalence of sleep disorders is driving the market over the forecast period. Along with this, the rise in awareness and high health care spending are also expected to drive the market. Other factors that will promote the demand for insomnia drugs includes rapidly growing geriatric population and rising prevalence of sleep disorders and stress.

Competitive Landscape

The insomnia treatment market is fragmented in nature owing to the presence of multiple generic manufacturers. A few players operating in the market offer branded drugs options, however, price sensitivity is an issue in several emerging regions. Additionally, major manufacturers are focusing on the development of new molecules to gain a competitive edge and tap the high unmet needs in the market. The major players in the market are Merck & Co., Mylan N.V., Paratek Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Ltd., Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Stress Due to Highly Active Lifestyle of Individuals
    • 4.2.2 Side Effects Due to Certain OTC and Prescription Medication
    • 4.2.3 High Usage of Media Devices before Sleep
  • 4.3 Market Restraints
    • 4.3.1 Misconceptions about the Seriousness of Insomnia
    • 4.3.2 Patient Non-Adherence due to Characteristic Side Effects of Insomnia Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 By Drug
      • 5.1.1.1 Benzodiazepines
      • 5.1.1.2 Nonbenzodiazepines
      • 5.1.1.3 Antidepressants
      • 5.1.1.4 Orexin Antagonist
      • 5.1.1.5 Melatonin Antagonist
      • 5.1.1.6 Other Treatment
    • 5.1.2 Devices
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies and Drug Stores
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co.
    • 6.1.2 Mylan N.V.
    • 6.1.3 Paratek Pharmaceuticals, Inc.
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Sanofi S.A.
    • 6.1.6 Sumitomo Dainippon Pharma Co., Ltd.
    • 6.1.7 Takeda Pharmaceutical Company Ltd.
    • 6.1.8 Teva Pharmaceutical Industries Ltd.
    • 6.1.9 Vanda Pharmaceuticals Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top